Suven Life Sciences Limited (BOM:530239)

Market Cap	98.21B +83.6%
Revenue (ttm)	88.14M +17.3%
Net Income	-3.52B
EPS	-14.74
Shares Out	263.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,192
Open	375.45
Previous Close	374.45
Day's Range	362.00 - 389.50
52-Week Range	124.35 - 389.50
Beta	0.80
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer’s disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathi...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1989
• Employees: 142
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530239

Financial Performance

In fiscal year 2026, Suven Life Sciences's revenue was 71.15 million, an increase of 6.89% compared to the previous year's 66.56 million. Losses were -2.76 billion, 71.9% more than in 2025.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 22, 2026

Data Sources Report a data error